Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Polycythemia Vera 2Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder 1Relapsed Pediatric Solid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Blood Stem Cell Transplantation 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 6fludarabine 5Exercise 4Blood Specimen Collection 4Surveys and Questionnaires 3Immunotherapy, Adoptive 3thymoglobulin 2pegylated granulocyte colony-stimulating factor 2Voriconazole 2Stem Cell Transplantation 2Saline Solution 2Physical Therapy Modalities 2Parenteral Nutrition 2Mycophenolic Acid 2Etoposide 2Cytarabine 2CF regimen 2BNT162 Vaccine 2Azacitidine 2venetoclax 1trihexyltetradecylphosphonium chloride 1treosulfan 1shengxuening 1ruxolitinib 1ramosetron 1monalizumab 1glucarpidase 1fludarabine phosphate 1ferrous succinate 1eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hematologic Neoplasms × ruxolitinib × Clear all
NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
50 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡